bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Group LLC in a research report issued to clients and investors on Wednesday.

Several other research firms also recently commented on BLUE. Maxim Group restated a “buy” rating and set a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research report on Monday. Leerink Swann restated an “outperform” rating and set a $145.00 target price (up previously from $120.00) on shares of bluebird bio in a research report on Friday, October 6th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Morgan Stanley downgraded bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price for the company. in a research report on Monday, October 2nd. Finally, Cantor Fitzgerald restated a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research report on Thursday, September 28th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. bluebird bio has an average rating of “Hold” and a consensus target price of $116.91.

bluebird bio (NASDAQ BLUE) opened at 131.65 on Wednesday. bluebird bio has a 52 week low of $37.05 and a 52 week high of $143.50. The company’s market capitalization is $6.00 billion. The company’s 50-day moving average price is $123.70 and its 200-day moving average price is $101.61.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same quarter in the prior year, the business posted ($1.59) EPS. bluebird bio’s revenue was up 977.4% compared to the same quarter last year. On average, equities analysts forecast that bluebird bio will post ($6.85) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Jefferies Group LLC Reiterates Hold Rating for bluebird bio, Inc. (BLUE)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/jefferies-group-llc-reiterates-hold-rating-for-bluebird-bio-inc-blue.html.

In other news, insider David Davidson sold 4,000 shares of bluebird bio stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $131.31, for a total value of $525,240.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sullivan sold 861 shares of bluebird bio stock in a transaction on Friday, August 4th. The shares were sold at an average price of $93.83, for a total value of $80,787.63. Following the completion of the sale, the insider now directly owns 5,924 shares of the company’s stock, valued at $555,848.92. The disclosure for this sale can be found here. Insiders sold a total of 126,879 shares of company stock valued at $15,401,808 over the last three months. Insiders own 3.90% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. increased its stake in shares of bluebird bio by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock valued at $1,096,000 after buying an additional 27 shares during the period. Teacher Retirement System of Texas increased its stake in shares of bluebird bio by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 53 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in shares of bluebird bio by 0.8% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock valued at $1,885,000 after buying an additional 140 shares during the period. Prudential Financial Inc. increased its stake in shares of bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 150 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of bluebird bio by 0.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock valued at $3,302,000 after buying an additional 151 shares during the period.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.